The index ‘Treatment Duration Control’ for enabling randomized controlled trials with variation in duration of treatment of chronic pain patients

BMC Medical Research Methodology

Robert J van Grootel¹  Hilbert W van der Glas¹ 

[1] Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, G05.129, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands

关键词: EQ-5D;    Quality of life;    Temporomandibular disorders;    Chronic pain;    Treatment duration;    Routine outcome monitoring;    Decision rules;    Randomized trial methodology;   

Others  :  866658
DOI  :  10.1186/1471-2288-13-123

 received in 2012-11-26, accepted in 2013-10-02,  发布年份 2013

【 摘 要 】

Background

Treatment duration varies with the type of therapy and a patient’s recovery speed. Including such a variation in randomized controlled trials (RCTs) enables comparison of the actual therapeutic potential of different therapies in clinical care. An index, Treatment Duration Control (TDC) of outcome scores was developed to help decide when to end treatment and also to determine treatment outcome by a blinded assessor. In contrast to traditional Routine Outcome Monitoring which considers raw score changes, TDC uses relative change.

Methods

Our theory shows that if a patient with the largest baseline scores in a sample requires a relative decrease by treatment factor T to reach a zone of low score values (functional status), any patient with smaller baselines will attain functional status with T. Furthermore, the end score values are proportional to the baseline. These characteristics concur with findings from the literature that a patient’s assessment of ‘much improved’ following treatment (related to attaining functional status) is associated with a particular relative decrease in pain intensity yielding a final pain intensity that is proportional to the baseline. Regarding the TDC-procedure: those patient’s scores that were related to pronounced signs and symptoms, were selected for adaptive testing (reference scores). A Contrast-value was determined for each reference score between its reference level and a subsequent level, and averaging all Contrast-values yielded TDC. A cut-off point related to factor T for attaining functional status, was the TDC-criterion to end a patient’s treatment as being successful. The use of TDC has been illustrated in RCT data from 118 chronic pain patients with myogenous Temporomandibular Disorders, and the TDC-criterion was validated.

Results

The TDC-criterion of successful/unsuccessful treatment approximated the cut-off separating two patient subgroups in a bimodal post-treatment distribution of TDC-values. Pain intensity decreased to residual levels and Health-Related Quality of Life (HRQoL) increased to normal levels, following successful treatment according to TDC. The post-treatment TDC-values were independent from the baseline values of pain intensity or HRQoL, and thus independent from the patient’s baseline severity of myogenous Temporomandibular Disorders.

Conclusions

TDC enables RCTs that have a variable therapy- and patient-specific duration.

【 授权许可】

   
2013 van der Glas and van Grootel; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Dao TTT, Lavigne GJ, Charbonneau JS, Feine JS, Lund JP: The efficacy of oral splints in the treatment of myofacial pain of the jaw muscles: a controlled clinical trial. Pain 1994, 56:85-94.
• [2]Rudy TE, Turk DC, Kubinski JA, Zaki HS: Differential treatment responses of TMD patients as a function of psychological characteristics. Pain 1995, 61:103-112.
• [3]Ekberg EC, Vallon D, Nilner M: Occlusal appliance therapy in patients with temporomandibular disorders: a double-blind controlled study in a short-term perspective. Acta Odontol Scand 1998, 56:122-128.
• [4]Turner JA, Mancl L, Aaron LA: Short- and long-term efficacy of brief cognitive-behavioral therapy for patients with chronic temporomandibular disorder pain: a randomized, controlled trial. Pain 2006, 121:181-194.
• [5]Beckerman H, Roebroeck ME, Lankhorst GJ, Becher JG, Bezemer PD, Verbeek ALM: Smallest real difference, a link between reproducibility and responsiveness. Quality Life Res 2001, 10:571-578.
• [6]Kropmans TJB, Dijkstra PU, van Veen A, Stegenga B, De Bont LGM: The smallest detectable difference of mandibular function impairment in patients with a painfully restricted temporomandibular joint. J Dent Res 1999, 78:1445-1449.
• [7]Van Grootel RJ, van der Bilt A, van der Glas HW: Long-term reliable change of pain scores in individual myogenous TMD patients. Eur J Pain 2007, 11:635-643.
• [8]Jacobson NS, Folette WC, Revenstorf D: Psychotherapy outcome research: methods for reporting variability and evaluating clinical significance. Behav Therapy 1984, 15:336-352.
• [9]Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change to psychotherap research. J Consulting Clin Psychology 1991, 59:12-19.
• [10]Wolfe F, O’Dell JR, Kavanaugh A, Wilske K, Pincus T: Evaluating severity and status in rheumatoid arthritis. J Rheumatol 2001, 38:1453-1462.
• [11]de Beurs E, den Hollander-Gijsman ME, van Rood YR, van der Wee NJA, Giltay EJ, van Noorden MS, van der Lem R, van Fenema E, Zitman FG: Routine outcome monitoring in the Netherlands: practical experiences wih a web-based strategy for the assessment of treatment outcome in clinical practice. Clin Psychol Psychother 2011, 18:1-12.
• [12]Meuldijk D, Carlier IVE, van Vliet IM, van den Akker-Marle ME, Zitman FG: A randomized controlled trial of the efficacy and cost-effectiveness of a brief intensified cognitive behavioral therapy and/or pharmacotherapy for mood and anxiety disorders: design and methods. Contemp Clin Trials 2012, 33:983-992.
• [13]van der Lem R, van der Wee NJA, van Veen T, Zitman FG: Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychother Psychosom 2012, 81:226-234.
• [14]Stutts LA, Robinson ME, McCulloch RC, Banou E, Waxenberg LB, Gremillion HA, Staud R: Patient-centered outcome criteria for successful treatment of facial pain and fibromyalgia. J Orofac Pain 2009, 23:47-53.
• [15]Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on a 11-point numerical pain rating scale. Pain 2001, 94:149-158.
• [16]van der Glas HW, Buchner R, van Grootel RJ: Vergelijking tussen behandelingsvormen bij myogene temporomandibulaire dysfunctie [Comparison between different types of therapy for myogenous temporomandibular disorders]. Ned Tijdschr Tandheelkd 2000, 107:505-512.
• [17]van Grootel RJ, van der Glas HW, Buchner R, de Leeuw JRJ, Passchier J: Patterns of pain variation related to myogenous temporomandibular disorders. Clin J Pain 2005, 21:154-165.
• [18]van Grootel RJ, van der Glas HW: Statistically and clinically important change of pain scores in patients with myogenous temporomandibular disorders. Eur J Pain 2009, 13:506-510.
• [19]Dolan P, Gudex C, Kind P, Williams A: A social tariff for EuroQoL: results from a UK general population survey. University of York: Centre for Health Economics; 1995. Discussion paper 138
• [20]Guyatt G, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987, 40:171-178.
• [21]Cohen J: Statistical power analysis for the behavioural sciences. London: Academic Press; 1969.
• [22]Husted JA, Cook RJ, Farewell VT, Gladman DD: Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000, 53:459-468.
• [23]Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation. Med Care 2003, 41:582-592.
• [24]Stratford PW, Binkley J, Solomon P, Finch E, Gill C, Moreland J: Defining the minimum level of detectable change for the Roland-Morris questionnaire. Phys Ther 1996, 76:359-365.
• [25]Heald SL, Riddle DL, Lamb RL: The shoulder pain and disability index: the construct validity and responsiveness of a region-specific disability measure. Phys Ther 1997, 77:1079-1089.
• [26]Miller GA: The magic number seven plus or minus two: some limits on our capacity for processing information. Psychol Rev 1956, 63:81-97.
• [27]Steiner DL, Norman GR: Health Measurement Scales, a Practical Guide to Their Development and use. Oxford: Oxford University Press; 2004.
• [28]Burström K, Johannesson M, Diderichsen F: Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001, 55:51-69.
• [29]Clark CT: Interocclusal appliance therapy. In A Textbook of Occlusion. Edited by Mohl ND, Zarb GA, Carlsson GE, Rugh JD. Chicago: Quintessence; 1988:271-284.
• [30]Greenwood LF: Masticatory muscle disorders. In Temporomandibular Joint and Masticatory Muscle Disorders. Edited by Zarb GA, Carlsson GE, Sessle BJ, Mohl ND. Copenhagen: Munksgaard; 1994:256-270.
• [31]Okeson JP: Orofacial Pain: Guidelines for Assessment, Classification, and Management. The American Academy of Orofacial Pain. Illinois: Quintessence; 1996.
• [32]Mrowietz U, Kragballe K, Reich K, Spuls P, Criffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N: Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011, 303:1-10.
• [33]Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A: Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. JEADV 2012, 26:133-1344.
• [34]Flytström I, Stenberg B, Svensson Å, Bergbrant I: Patient’s Visual analogue scale: a useful method for assessing psoriasis severity. Acta Derm Venereol 2012, 92:339-409.
• [35]Group EQ: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
• [36]Kropmans TJB, Dijkstra PU, Stegenga B, Stewart R, de Bont LGM: Smallest detectable difference in outcome variables related to painful restriction of the temporomandibular joint. J Dent Res 1999, 78:784-789.